Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 3,223 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 3,223 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $174.17, for a total value of $561,349.91. Following the completion of the sale, the chief executive officer directly owned 315,407 shares of the company’s stock, valued at $54,934,437.19. The trade was a 1.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

William Lewis also recently made the following trade(s):

• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Down 3.3%

Shares of INSM stock traded down $5.73 during trading hours on Thursday, reaching $170.27. 2,588,589 shares of the company’s stock were exchanged, compared to its average volume of 2,142,398. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The stock has a market cap of $36.31 billion, a PE ratio of -27.51 and a beta of 1.08. The stock’s fifty day moving average price is $190.79 and its two-hundred day moving average price is $151.24.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.27) earnings per share. Research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $173,000. Resolute Capital Asset Partners LLC acquired a new stake in Insmed during the second quarter valued at $2,748,000. Caxton Associates LLP purchased a new position in Insmed in the first quarter valued at $441,000. Assenagon Asset Management S.A. raised its position in shares of Insmed by 84.5% in the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after acquiring an additional 33,626 shares during the period. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Insmed during the 2nd quarter worth about $5,578,000.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Jefferies Financial Group set a $269.00 price target on Insmed in a research report on Wednesday, December 10th. Redburn Partners set a $263.00 price objective on Insmed in a research note on Thursday, December 4th. Wedbush set a $203.00 target price on Insmed in a research report on Thursday, December 18th. UBS Group cut their price target on shares of Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Citigroup restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.